Skip to content

Clinical Study on the Effect of Fengyin Decoction in Treating Parkinson's Disease with Heat-Excess and Wind-Movement Syndrome in the Early-to-Mid Stages Based on the "Brain-Gut Axis" Theory

Clinical Study on the Effect of Fengyin Decoction in Treating Parkinson's Disease with Heat-Excess and Wind-Movement Syndrome in the Early-to-Mid Stages Based on the "Brain-Gut Axis" Theory

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2026001485
Enrollment
Unknown
Registered
2026-06-10
Start date
2023-08-08
Completion date
Unknown
Last updated
2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Control group:Basic treatment
Observation Group:Basic Treatment and Fengyin Decoction 200ml bid

Sponsors

Jiangsu Province Hospital of TCM
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Age =18 years, no gender restrictions; 2. Meets clinical diagnostic criteria for Parkinson's disease; 3. Hoehn and Yahr stage 1–3; 4. Meets Traditional Chinese Medicine diagnostic criteria for tremor syndrome, with pattern differentiation as heat-excess wind-movement syndrome; 5. Voluntary participation with signed written informed consent, good compliance, willingness to attend follow-up appointments, and ability to self-attend hospital visits. The informed consent process must comply with GCP regulations.

Exclusion criteria

Exclusion criteria: 1. Parkinson's syndrome, such as that caused by medication, trauma or infection, or Parkinson's-overlapping syndromes such as multiple system atrophy, progressive supranuclear palsy and corticobasal degeneration; 2. Patients with severe cardiac, pulmonary, hepatic or renal impairment (e.g. transaminases > 1.5 times the upper limit of normal, or serum creatinine exceeding the upper limit of normal); 3. Pregnant or breastfeeding women; 4. Severe cognitive impairment affecting the description of symptoms and the assessment of subjective function; 5. Patients currently participating in other drug clinical trials within the past month; 6. Other conditions, as judged by the investigator, that may reduce the likelihood of enrolment or complicate the enrolment process, such as frequent changes in the working environment that may lead to loss to follow-up; 7. Factors affecting gastrointestinal function: acute or chronic primary gastrointestinal diseases such as coeliac disease, autoimmune gastritis, inflammatory bowel disease, or irritable bowel syndrome; 8. Factors affecting the gastrointestinal microbiota: gastrointestinal and respiratory tract infections, food poisoning, or antibiotic treatment within the past month.

Design outcomes

Primary

MeasureTime frame
Non-Motor Symptoms Scale(NMSS);Traditional Chinese Medicine Syndrome Scoring;

Secondary

MeasureTime frame
MDS Unified Parkinson's Disease Rating Scale(MDS UPDRS);Patient Assessment of Constipation Symptoms (PAC-SYM);Pittsburgh Sleep Quality Index (PSQI);

Countries

china

Contacts

Public Contactzhengyan

Jiangsu Province Hospital of TCM

260019@njucm.edu13601580292

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Jun 29, 2026